Liver Cirrhosis
Conditions
Brief summary
The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or hospitalization, in subjects with early decompensated liver cirrhosis. Rifaximin, a non-systemic antibacterial agent, is currently marketed as a 550 mg tablet for the reduction in risk of recurrent overt hepatic encephalopathy, a complication of liver cirrhosis. The rifaximin SSD tablet was formulated to maximize the efficacy of rifaximin. Subjects will receive 1 of 5 doses of rifaximin SSD tablets or placebo tablets every day for 24 weeks.
Interventions
DRUGPlacebo
DRUGRifaximin SSD 80 mg IR tablet
DRUGRifaximin SSD 40 mg SER tablet
DRUGRifaximin SSD 80 mg SER tablet
DRUGRifaximin SSD 80mgIR/80mgSER tablet
Sponsors
Bausch Health Americas, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of liver cirrhosis and documented ascites. * Model End Stage Liver Disease (MELD) score of at least 12, MELD Na of at least 12, or Child-Pugh B (score of 7 - 9). * If applicable, has a close family or other personal contacts who can provide continuing oversight to the patient and will be available to the patient during the conduct of the trial. * If female of childbearing potential, have a negative serum pregnancy test at study start and agree to use an acceptable method of contraception during the study.
Exclusion criteria
* History of a major psychiatric disorder including uncontrolled major depression or controlled or uncontrolled psychoses within the past 24 months prior to study start. * History of alcohol abuse or substance abuse within the past 3 months prior to study start. * Documented cholestatic liver disease such as primary sclerosing cholangitis. * Had prophylactic variceal banding within 2 weeks or is scheduled to undergo prophylactic banding during the study. * Diagnosed with an infection for which the patient is currently taking oral or parenteral antibiotics. * Significant hypovolemia, or any electrolyte abnormality that can affect mental function (eg, serum sodium \< 125 mEq/L, serum calcium \> 10 mg/dL). * Severe hypokalemia, defined as serum potassium concentration \< 2.5 mEq/L. * Anemic, defined as hemoglobin concentration ≤ 8 g/dL. * Renal insufficiency with a creatinine of ≥ 1.5 mg/dL. * Presence of intestinal obstruction or inflammatory bowel disease. * Uncontrolled Type 1 or Type 2 diabetes. * History of seizure disorders. * Unstable cardiovascular or pulmonary disease, categorized by a worsening in the disease condition that requires a change in treatment or medical care within 30 days of study start. * Active malignancy within the last 5 years (exceptions: basal cell carcinomas of the skin, or if female, in situ cervical carcinoma that has been surgically excised). * Has hepatocellular carcinoma. * Known human immunodeficiency virus, varicella, herpes zoster, or other severe viral infection within 6 weeks of study start. * Positive stool test for Yersinia enterocolitica, Campylobacter jejuni, Salmonella, Shigella, ovum and parasites, and/or Clostridium difficile (C. difficile); determined during the screening period prior to study start. * History of tuberculosis infection and/or has received treatment for a tuberculosis infection. * History of hypersensitivity to rifaximin, rifampin, rifamycin antimicrobial agents, or any of the components of rifaximin soluble solid dispersion. * Used any investigational product or device, or participated in another research study within 30 days prior to study start.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to all-cause mortality or hospitalization that is attributable to complications of liver disease. | Weeks 1 through 24 | The primary outcome measure will evaluate the time from start of the treatment period to death due to any cause (all-cause mortality) or hospitalization due to complications of liver disease for each patient during the 24-week treatment period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics of rifaximin and its metabolite. | Weeks 1 through 24 | This outcome will measure the plasma levels of rifaximin and its metabolite (25-desacetyl rifaximin) for each patient during the 24-week treatment period. |
| Incidence of treatment-emergent adverse events. | Weeks 1 through 24 | This outcome will evaluate the incidence of treatment-emergent adverse events (percentage of patients who experience adverse events following the start of the treatment period). |
| Overall hospitalization rate due to each complication of liver disease or all-cause mortality over the 24-week treatment period. | Weeks 1 through 24 | This outcome measure will determine the rate of hospitalization (percentage of patients who are hospitalized) due to each complication of liver disease or all-cause mortality over the 24-week treatment period. |
| Changes in electrocardiogram measurements | Weeks 1 through 24 | This outcome will measure the changes in measurements obtained from 12-lead electrocardiograms for each patient during the treatment period. |
| Changes in indices of health outcomes | Weeks, 4, 8, 12, 16, and 24 | This outcome will evaluate each patient's responses on questionnaires that assess health status. |
| Change in clinical laboratory parameters. | Weeks 1 through 24 | This outcome will measure the changes in each patient's clinical laboratory test results during the treatment period. |
Countries
Russia, United States
Outcome results
None listed